Thus, despite important differences in phenotype measurement, results from ROSMAP and A4 suggest a coherent biology: microglia may exacerbate tau pathology starting from the preclinical stage of AD, while other cell types may contribute to tau pathology later in the symptomatic disease stages. This evidence concerns the gene MAPT and Alzheimer disease.